Skip to main content
Article
Combination therapy with mTOR and PI3 kinase inhibitors is broadly synergistic in a wide variety of endometrial cancer cells
Proceedings in Obstetrics and Gynecology
  • Shujie Yang, University of Iowa
  • Xue Xiao, University of Iowa
  • Xiangbing Meng, University of Iowa
  • Kimberly K. Leslie, University of Iowa
Peer Reviewed
0
Publication Date
7-28-2011
Abstract

Dysregulation of mammalian target of rapamycin (mTOR) signaling has been found in many human tumors, including endometrial cancer, and mTOR inhibitors have been utilized in clinical trials as targeted therapies with only limited success. Herein we identify a viable treatment alternative that overcomes temsirolimus-induced AKT phosphorylation in endometrial cancer. Our data suggest temsirolimus and BEZ235 inhibit different components of the AKT/mTOR signaling pathway to accomplish synergistic pathway inhibition, which is necessary for therapeutic efficacy to abrogate the increased signaling through AKT that occurs with mTOR inhibition alone

Keywords
  • PI3K,
  • Akt,
  • mammalian target of rapamycin,
  • temsirolimus,
  • BEZ235,
  • endometrial cancer
Total Pages
2
Rights
Copyright © Shujie Yang, Xue Xiao, Xiangbinb Meng, and Kimberly K. Leslie, 2011.
Creative Commons License
Creative Commons Attribution 3.0
Citation Information
Shujie Yang, Xue Xiao, Xiangbing Meng and Kimberly K. Leslie. "Combination therapy with mTOR and PI3 kinase inhibitors is broadly synergistic in a wide variety of endometrial cancer cells" (2011) p. 1 - 2 ISSN: 2154-4751
Available at: http://works.bepress.com/xiangbing_meng/4/